TG THERAPEUTICS

TG Therapeutics presented updated ENHANCE Phase 3b trial data on BRIUMVI® (ublituximab-xiiy) for relapsing forms of multiple sclerosis (RMS) at the 2024 ECTRIMS annual meeting, highlighting successful transition from prior anti-CD20 treatment and safe 30-minute infusions with mild reactions.

FDA approves subcutaneous versions of Roche's biologic drugs: Tecentriq Hybreza for cancer (7-min injection, 3.8B Swiss francs revenue) and Ocrevus Zunovo for MS (10-min injection, 6.4B Swiss francs revenue), both offering faster dosing times and broader accessibility.

Roche's injectable Ocrevus, approved by FDA, shortens MS treatment time from hours to 10 minutes, available from October, reducing need for specialized infusion centers and potentially aiding competition defense.

S&P Dow Jones Indices to adjust S&P 500, S&P MidCap 400, and S&P SmallCap 600 indices on Sept 23, ensuring market cap representation. Palantir, Dell, and Erie Indemnity to join S&P 500, replacing American Airlines, Etsy, and Bio-Rad Laboratories. American Airlines to replace TEGNA in S&P MidCap 400, and TEGNA to replace Designer Brands in S&P SmallCap 600. Etsy to replace Haverty Furniture in S&P SmallCap 600. Bio-Rad Laboratories to replace Erie Indemnity in S&P MidCap 400.